NCT02959619已完成1 期
Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer
详细描述
The initial purpose of the study is to determine the largest amount of ensartinib that can be safely given to humans. An expansion phase will be conducted to assess the preliminary anti-tumor activity in ALK-positive non-small cell lung cancer once the recommended Phase 2 dose has been established.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy
- •For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations positive by FISH or IHC
- •Eastern Cooperative Group ECOG) Performance Status score of 0 or 1
- •Adequate organ system function
- •Male patients willing to use adequate contraceptive measures; female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures
- •Measurable disease per RECIST
- •Willingness and ability to comply with the trial and follow-up procedures
- •Written informed consents are required to indicate that the patients are aware of the investigational nature of the study
排除标准
- •Current use of anticancer therapy.
- •Use of an investigational drug within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of ensartinib
- •Any major surgery, radiotherapy, or immunotherapy within the last 21 days.
- •Chemotherapy regimens with delayed toxicity within the last 4 weeks.
- •Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks.
- •Prior stem cell transplant
- •Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to ensartinib or to the active ingredient of ensartinib
- •Prior use of ALK TKIs with the exception of crizotinib
- •Primary CNS tumors or meningeal metastasis
- •Pregnant or breastfeeding female
- •Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of ensartinib
- •Clinically significant cardiovascular disease.
- •Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
- •Concurrent condition evaluated by investigator would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled
- •Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
研究组 & 干预措施
Ensartinib
Experimental
Escalating dose of ensartinib was orally given once er day
干预措施: Ensartinib (Drug)
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 12 months
次要结局
- Peak Plasma Concentration (Cmax)(12 months)
- Area under the plasma concentration versus time curve (AUC)(12 months)
- Half-life time(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 MutationSolid TumorAngioimmunoblastic T-cell LymphomaChondrosarcomaGliomaIntrahepatic CholangiocarcinomaNCT02273739Celgene21
已完成
1 期
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic TumorsNonhematologic Neoplasms, AdvancedNCT02699749Millennium Pharmaceuticals, Inc.80
已完成
1 期
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid TumorsNeoplasms, Advanced SolidNCT02525536Takeda18
已完成
1 期
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)HypophosphatasiaNCT04980248Alexion Pharmaceuticals, Inc.15
Unknown
1 期
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsSolid TumorsNCT03634982Revolution Medicines, Inc.133